June 21, 2017

Robert Delongchamp, PhD



1993 – Ph.D. (Statistics), Oregon State University
1973 – MPH (Biostatistics), University of Michigan
1971 – BS (Mathematics & Biology), Northern Michigan Univ

Research Interest

Dr. Delongchamp is a professor in the Departments of Epidemiology and an adjunct professor in the Department of Biomedical Informatics at the University of Arkansas for Medical Sciences, and a contract employee consultant to the Center for Public Health Practice at the Arkansas Department of Health.

During my career, I have worked at the National Center for Toxicological Research (20 years), the Radiation Effects Research Foundation (5 years), and Dow Corning Corporation (4 years).  At NCTR my research interests were to provide a sound scientific interpretation of the toxicological or epidemiological data that underlie risk assessments; in particular statistical issues associated with emerging technologies in genetic studies.  At RERF, I evaluated the mortality and cancer incidence in the cohort of in utero exposed atomic bomb survivors in Hiroshima and Nagasaki.  At DCC, I evaluated data on silicone medical devices such as joint replacements and breast implants.

Since coming to the University of Arkansas for Medical Sciences, I have continued to work on methods to deal with multiple comparison issues in analyses of ‘omics data.  I am developing methods to estimate disease rates in small areas, e.g., census block groups.  These estimates have been used by the Arkansas Department of Health to target interventions and to evaluate disease clusters.

Selected Publications

Todorova VK, Beggs ML, Delongchamp RR, Dhakal I, Makhoul I, Wei JY, Klimberg VS. Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model. PLoS One. 2012;7:e48398

Shmookler Reis RJ, Ayyadevara S, Crow WA, Lee T, Delongchamp RR. Gene categories differentially expressed in C. elegans age-1 mutants of extraordinary longevity: New insights from novel data-mining procedures. J Gerontol A Biol Sci Med Sci. 2011

Delongchamp RR, Razzaghi M, Lee T. Estimating false discovery rate and false non-discovery rate using the empirical cumulative distribution function of p-values in ‘omics’ studies. Genes & Genomics. 2011;33:461-466

Valentine CR, Delongchamp RR, Pearce MG, Rainey HF, Dobrovolsky VN, Malling HV, Heflich RH. In vivo mutation analysis using the FX174 transgenic mouse and comparisons with other transgenes and endogenous genes. Mutat Res. 2010;705:205-216

Delongchamp RR, Velasco C, Desai V, Lee T, Fuscoe J. Designing toxicogenomics studies that use DNA array technology. Bioinformatics and Biology Insights. 2008;2:323-334

Delongchamp RR, Lee T, Velasco C. A method for computing the overall statistical significance of a treatment effect among a group of genes. BMC Bioinformatics. 2006;7:S11

Delongchamp RR, Bowyer JF, Chen J, Kodell RL. Multiple-testing strategy for analyzing cDNA array data on gene expression. Biometrics. 2004;60:774-782

Delongchamp RR, Malling HV, Chen JB, Heflich RH. An estimator of the mutant frequency in assays using transgenic animals. Mutation Research-Genetic Toxicology & Environmental Mutagenesis. 1999;440:101-108

Delongchamp RR, Mabuchi K, Yoshimoto Y, Preston DL. Cancer mortality among atomic bomb survivors exposed in utero or as young children, October 1950-May 1992. Radiation Research. 1997;147:385-395

Cook RR, Delongchamp RR, Woodbury M, Perkins LL, Harrison MC. The prevalence of women with breast implants in the United States–1989. Journal of Clinical Epidemiology. 1995;48:519-525

Yoshimoto Y, Delongchamp R, Mabuchi K. In-utero exposed atomic bomb survivors: Cancer risk update [letter]. Lancet. 1994;344:345-346